CannaRoyalty and Aequus Pharmaceuticals Announce Joint Venture to Develop and Commercialize Cannabis-Based Therapies Targeting Neurological Disorders

CannaRoyalty to contribute Bodhi Research position into the JV in exchange for equity OTTAWA, Jan. 11, 2018 /PRNewswire/  CannaRoyalty Corp. (CSE: CRZ) (OTCQX: CNNRF) ( CannaRoyalty ) and Aequus Pharmaceuticals Inc. (TSX-V: AQS) (OTCQB: AQSZF) ( Aequus ) (together the Partners ), today announced a collaboration (the JV ) to advance a suite of cannabis-based therapies targeting neurological disorders into clinical trials in Canada, in collaboration with Canadian doctors and key opinion leaders. CannaRoyalty and Aequus have formed this collaboration to clinically advance a number of cannabis-based therapies in partnership with Canadian
http://bit.ly/2FtpgIK